Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorpucitinib in Familial Adenomatous Polyposis
NCT05014360Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of lorpucitinib in familial adenomatous polyposis (FAP), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage Change from Baseline in Colorectal Polyp Burden for all Polyps at Week 24 and Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24. Started Nov 2021; status: completed.
02
Drugs
lorpucitinib
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT05014360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014360.